US 12,152,078 B2
Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3
Tobias Raum, Munich (DE); Ines Herrmann, Munich (DE); Patrick Hoffmann, Munich (DE); Peter Kufer, Munich (DE); Markus Muenz, Munich (DE); and Doris Rau, Munich (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on Sep. 20, 2021, as Appl. No. 17/479,156.
Application 16/676,170 is a division of application No. 15/225,627, filed on Aug. 1, 2016, granted, now 10,519,241.
Application 17/479,156 is a continuation of application No. 16/676,170, filed on Nov. 6, 2019, granted, now 11,155,629.
Claims priority of provisional application 62/290,861, filed on Feb. 3, 2016.
Claims priority of provisional application 62/199,945, filed on Jul. 31, 2015.
Prior Publication US 2022/0064308 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/39558 (2013.01); C07K 16/2809 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/94 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A nucleic acid encoding a bispecific antibody construct comprising a first binding domain which binds to human epidermal growth factor receptor VIII (EGFRVIII) on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell, wherein the first binding domain comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 157 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 158.